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Word count: 1608 Tables: 0   Figures: 2 We look forward to your response in due course. Peripheral arterial disease is an most important independent risk factor for the development of foot ulceration, limb loss and overall mortality. However, its diagnosis in diabetes is challenging due to the presence of neuropathy and calcification. Commonly used bedside tests either have low sensitivities or little evidence to justify their use.
Yours sincerely,
Duplex ultrasound (DUS) has good correlation to angiography findings but a full scan is difficult to learn and time consuming to perform. We have previously demonstrated that a focused DUS of the distal anterior and posterior tibial arteries at the ankle (The Podiatry Ankle Duplex scan; PAD-scan), can be readily learned by novices and performed rapidly and accurately.
The primary aim of this study is to determine the diagnostic accuracy of the PADscan and other commonly used bedside tests in detecting arterial disease in diabetes.
Methods and analysis:
The study will include 305 patients presenting to diabetic foot clinics at two centers. Arterial assessment will be performed using the following index tests:
the PAD-scan, pulse palpation, audible handheld Doppler, ankle-brachial pressure index (ABPI), toe-brachial pressure index (TBPI) and transcutaneous pressure of oxygen (TcPO2). Patients will then undergo a full lower limb arterial DUS by a blinded vascular scientist as a reference test.
Ethics and Dissemination:
Approval was gained from NRES Committee London (REC reference 17/LO/1447). Findings will be disseminated by various methods including international presentations and publication in a peer-reviewed journal.
Trial registration number: ClinicalTrials.gov Identifier NCT04058626
Word count: 236 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (1) . In England and Wales alone, up to 75,000 people with diabetes will have a foot ulcer at any given time (2) . Ulcers are also challenging to manage, necessitating intensive treatment associated with major healthcare consumption and high costs (2) . The aetiology of diabetic foot ulcers is multifactorial and the patient population diverse (3) . Neuropathy and peripheral arterial disease (PAD) are the most important aetiological factors and depending on the patient or population, either may be the predominant feature. With rising prevalence of PAD in western populations, there has been a shift of pattern from neuropathic to 'neuro-ischaemic' ulceration (4) (5) (6) . The prompt and accurate detection of PAD in the ulcerated foot is time critical as time to revascularisation is a determinant of ulcer healing and limb salvage (7, 8) .
Importantly, due to the confounding effects of neuropathy and arterial calcification, the detection of PAD in diabetes is challenging. Symptoms, such as claudication and rest pain are often masked by the presence of neuropathy. Furthermore, physical examination and bedside screening tests such as ankle brachial pressure indices (ABPI) are hindered by the presence of calcified, incompressible blood vessels. Limited evidence suggests that toe brachial pressure indices (TBPI) and transcutaneous pressure of oxygen (TcPO2) may be superior to ABPI measurements (9, 10) . However, TBPI may also be influenced by the presence of digital artery calcification and TcPO2 can be time consuming to perform and may not be feasible in real world diabetic foot practice, reportedly used 6.2 and 0.8% respectively (11) . Interpretation of audible Doppler arterial signals using hand held Doppler devices is the most commonly used bedside test, but this is also limited by significant inter-observer variation and poor sensitivity in detecting PAD (12, 13) . Currently, there is a scarcity of robust evidence to support the use of any one test (9) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y The limitations of current bedside tests highlight a need for a more accurate and reliable non-invasive screening tool for the detection of arterial disease. The lack of evidence highlights the need for a comparative diagnostic accuracy study to identify the best screening strategy.
Point-of-care arterial duplex ultrasound may provide an alternative solution to diagnosis. A full lower limb arterial DUS scan has an accuracy comparable to the gold standard of angiography (14) but is too time consuming to perform and technically challenging to learn due to the difficulty of scanning proximal tibial vessels (15), thus limiting its utility as a bed-side test by front line staff. The primary aim of this present study is to determine the ability of the PAD-scan, continuous handheld Doppler (audible and visual waveform assessment), ABPI, TBPI, TcPO2 and pulse palpation to discriminate between the presence and absence of PAD in diabetes, as compared to a reference standard of full lower limb arterial DUS. 
METHODS AND ANALYSIS

Study status:
This is an on going study that started recruiting on 4 th March 2019.
Design
Inclusion and exclusion criteria:
Diabetic patients aged over 18 years presenting to the diabetic foot clinics at our chosen Centre's will be eligible for the study. Patients with a known history of vascular imaging or intervention in the past 1 year will be excluded. Patients unable to provide informed consent will also be excluded.
Intervention(s) or method:
Patient assessment:
The clinical team responsible for care will perform a routine clinical assessment of each patient. Neuropathy will be tested for using a 10-g monofilament, 128Hz
tuning fork and proprioception at the first metatarsophalangeal joint.
Assessment of ulcer size, depth and severity will be made using the validated University of Texas (UT) Score (17,18).
Index tests:
Pulse palpation and audible handheld continuous Doppler assessment will be performed by the Podiatrist assessing the patient as part of their routine clinical assessment.
This present study focuses on diagnostic accuracy and not feasibility of frontline staff learning or performing the PAD-scan, which we have previously established. Therefore, two vascular scientists will perform all tests, one of the two will perform the index tests; PAD-scan, TcPO2, ABPI, TBPI and visual handheld continuous Doppler waveform assessment, the other will perform the reference full Duplex scan. Each scientist will be blinded to the findings of the other.
 Pulse palpation
The dorsalis pedis (DPA) and posterior tibial artery (PTA) pulses will be palpated and classified as present or absent. Absence of either pulse will be considered diagnostic. The DPA and PTA will be interrogated using a continuous wave hand held Doppler device. The presence of a monophasic signal or the absence of a signal in either vessel will be considered diagnostic.
 Continous handheld Doppler device (audible and visual waveform assessment)
 ABPI
A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
The pressures of both arms will also be taken and the highest reading used to calculate the ABPI (19). ABPI of ≤ 0.9 (52) or >1. 3 (20) in either vessel will be considered diagnostic.  TBPI TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger. The highest upper limb reading will be used to calculate the TBPI. Values of <0.75 will be considered diagnostic for PAD (21).
 TcPO2
Measurements will be taken at 2 locations on the dorsum of the foot using an automated machine equipped with Clark electrodes. Calibration will be performed and transducers placed on the skin after cleaning using double-sided adhesive rings and contact liquid (22). Readings of <40mmHg in either electrode will be considered diagnostic (23). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Intra-arterial digital subtraction angiography (DSA) has long been considered the gold standard for diagnosis of PAD. However, it is expensive, invasive and carriers a risk of complications. DUS has been shown to be comparable to DSA, making it a useful non-invasive alternative (14) .
Patients will undergo a full departmental DUS at their respective hospitals on the same day as the index tests by one of two blinded vascular scientists present in each clinic. PAD will be deemed significant when occlusions, or stenosis, or diffuse stenotic disease, individually or collectively, cause significant velocity change and flow disturbance locally and result in biphasic or monophasic signal distally. All scans will be performed using the Mindray M7 (Shenzhen, China)
Portable Ultrasound System with a linear 6-14 kHz transducer.
Quality assurance:
PAD-scan: For quality assurance, an external vascular scientist will review a random selection of 40 saved scans.
Reference test: Quality will be assured by acquiring a second DUS by an external vascular scientist in 20 individuals.
Statistical analysis and plan:
Sample size and power calculations:
Calculations were performed using the described sample size formula for estimating sensitivity (24). Calculations were based on a 95% confidence level (i.e. an error of 5%), an estimated PAD prevalence of 50% (25) and a predicted sensitivity of 90% for the PAD-scan as derived from our previous research. The estimated sample size required was calculated as 277 patients. From previous research undertaken, we anticipate an attrition rate of 10%. Therefore the recruitment target for tis study is 305 patients.
Statistical tests:
Cross-tabulation of the index test results by the results of the reference standard 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y will be made creating a 'confusion matrix'. This will be used to determine diagnostic accuracy, expressed as sensitivity, specificity, positive predictive and negative predictive values. Receiver operating characteristic (ROC) analysis will also be performed for each test. Agreement between tests will be analysed using the Cohen's kappa statistic. Statistical modeling will also be performed to explore the effect of combining tests on diagnostic accuracy.
Ethics
Ethics Committee approval: NHS Health Research Authority (NRES Committee
London-City & East Research Ethics Committee) approval gained on 21/12/2017 (REC reference 17/LO/1447).
Interim analysis and stopping rules:
No interim analysis will be performed, and the data will be analysed when the target recruitment of 305 patients has been reached.
PATIENT AND PUBLIC INVOLVEMENT
Patient representatives were involved in the design of this project protocol. In particular they informed the recruitment process in order to ensure that it was acceptable to patients. After completion of the study they will also be invited to a roundtable discussion of our findings, allowing for integration of their perspectives with those of practitioners. They will also be involved in the dissemination of our findings via patient groups and the production of written and video summaries for patients.
DISSEMINATION
The results of the study will be published a peer-reviewed journal and presented at international surgical and diabetes research meetings. Furthermore, to ensure that our findings reach all stakeholders including patients our results will also be presented at relevant patient group meetings as well as local and regional diabetic foot network meetings. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence -details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.
Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence. In the UK, over 7,000 amputations are performed each year because of diabetes.
Up to 80% of these are preceded by a foot ulcer and could therefore be prevented with improvements ulcer care. Peripheral arterial disease is an important risk factor for the development of diabetic foot ulceration. However, its diagnosis in diabetes is challenging due to the presence of neuropathy and arterial calcification. Commonly used bedside tests either have low sensitivities or little supporting evidence to justify their use.
Duplex ultrasound (DUS) has good correlation to angiography findings but a full scan is difficult to learn and time consuming to perform. We have previously demonstrated that a focused DUS of the distal anterior and posterior tibial arteries at the ankle (Podiatry Ankle Duplex scan; PAD-scan), can be readily learned by novices and performed rapidly and accurately.
Methods and analysis:
Ethics and Dissemination:
Trial registration number: ClinicalTrials.gov Identifier NCT04058626
Word count: 267  Appropriately statistically powered.
 One potential limitation of this work is that it focuses on a population with advanced disease and a high prevalence of peripheral arterial disease. However, these are also the most challenging group of patients to diagnose and where evidence is most lacking. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Furthermore, physical examination and bedside screening tests such as ankle brachial pressure indices (ABPI) are hindered by the presence of calcified, incompressible blood vessels. Limited evidence suggests that toe brachial pressure indices (TBPI) and transcutaneous pressure of oxygen (TcPO2) may be superior to ABPI measurements (11) (12) (13) . However, TBPI may also be influenced by the presence of digital artery calcification and TcPO2 can be time consuming to perform and may not be feasible in real world diabetic foot practice, reportedly used 6.2 and 0.8% respectively (14) . Interpretation of audible Doppler arterial signals using hand held Doppler devices is the most commonly used bedside test, but this is also limited by significant inter-observer variation and poor sensitivity in detecting PAD (15,16). Currently, there is a scarcity of robust evidence to support the use of any one test (11) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We have previously demonstrated that the PAD-scan can be readily learned and accurately performed by front line staff (19).
The primary aim of this present study is to determine the ability of the PAD-scan, continuous handheld Doppler (audible and visual waveform assessment), ABPI, TBPI, TcPO2 and pulse palpation to discriminate between the presence and absence of PAD in diabetes, as compared to a reference standard of full lower limb arterial DUS.
The results of this study will improve the diagnosis of PAD in diabetes and inform referral pathways between primary and secondary care. Early detection, referral and management of PAD in the ulcerated foot will result in faster healing rates, reduction in hospital admissions, reduction in lower limb amputations and cost savings for the NHS. In the non-ulcerated foot, detection of PAD may alter foot care behaviours to reduce the risk of ulceration and allow for optimisation of best medical therapy to reduce overall cardiovascular risk. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Study status: This is an ongoing study that started recruiting on 4 th March 2019.
Design
Inclusion and exclusion criteria:
Intervention(s) or method:
Patient assessment:
Assessment of ulcer size, depth and severity will be made using the validated University of Texas (UT) Score (20,21).
Index tests:
This present study focuses on diagnostic accuracy and not feasibility of frontline staff learning or performing the PAD-scan, which we have previously established. Therefore, two vascular scientists will perform all tests, one of the two will perform the index tests; PAD-scan, TcPO2, ABPI, TBPI and visual handheld continuous Doppler waveform assessment, the other will perform the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
 Pulse palpation
The dorsalis pedis (DPA) and posterior tibial artery (PTA) pulses will be palpated and classified as present or absent. Absence of either pulse will be considered diagnostic.
 Continous handheld Doppler device (audible and visual waveform assessment)
The DPA and PTA will be interrogated using a continuous wave handheld Doppler device. The presence of a monophasic signal or the absence of a signal in either vessel will be considered diagnostic. Secondary analysis will also consider the inclusion of biphasic waveforms to the diagnostic criteria.
 ABPI
The pressures of both arms will also be taken and the highest reading used to calculate the ABPI (22). ABPI of ≤ 0.9 will be considered diagnostic. Secondary analysis will consider the inclusion of ABPI >1.3 (23) to the diagnostic criteria. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger. The highest upper limb reading will be used to calculate the TBPI. Values of <0.75 will be considered diagnostic for PAD (24).
 TcPO2
Prior to taking TcPO2 measurements, patients will be acclimatized for 20 minutes in the resting supine position with the room temperature maintained between 23 and 25 C. Calibration will be performed and transducers placed on the skin after cleaning using double-sided adhesive rings and contact liquid (25).
Measurements will be taken centrally (at the sternum or the deltoid if the patient has had a previous midline sternotomy) and on the dorsum of the foot using an automated machine equipped with Clark electrodes. Foot measurements will be repeated after 3 minutes of 30 leg elevation supported by a wedge. Readings of <40mmHg at resting supine position in the foot electrode will be considered diagnostic (26). Regional Perfusion Index (RPI, limb TcPO2 values normalised to central values; values <0.6 considered diagnostic) and change in TcPO2 on leg elevation (decrease of >10mmHg considered diagnostic) will also be calculated as secondary TcPO2 metrics of interest for PAD diagnosis.
Reference test:
Intra-arterial digital subtraction angiography (DSA) has long been considered the gold standard for diagnosis of PAD. However, it is expensive, invasive and carriers a risk of complications. DUS has been shown to be comparable to DSA, making it a useful non-invasive alternative (17).
Patients will undergo a full departmental DUS at their respective hospitals on the same day as the index tests by one of two blinded vascular scientists present in each clinic. PAD will be deemed significant when occlusions, or stenosis, or diffuse stenotic disease, individually or collectively, cause significant velocity change (peak systolic velocity ratio (PSVR) 2) and flow disturbance locally and result in biphasic or monophasic signal distally. All scans will be performed using 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Quality assurance:
Statistical analysis and plan:
Sample size and power calculations:
Calculations were performed using the described sample size formula for estimating sensitivity (27). Calculations were based on a 95% confidence level (i.e. an error of 5%), an estimated PAD prevalence of 50% (28) and a predicted sensitivity of 90% for the PAD-scan as derived from our previous research. The estimated sample size required was calculated as 277 patients. From previous research undertaken, we anticipate an attrition rate of 10%. Therefore, the recruitment target for this study is 305 patients.
Statistical tests:
Cross-tabulation of the index test results by the results of the reference standard will be made creating a 'confusion matrix'. This will be used to determine diagnostic accuracy, expressed as sensitivity, specificity, predictive values and likelihood ratios. Receiver operating characteristic (ROC) analysis will also be performed for each test. Agreement between tests will be analysed using the Cohen's kappa statistic. Statistical modeling will also be performed to explore the effect of combining tests on diagnostic accuracy in order to identify the most accurate diagnostic strategy. 
Ethics
PATIENT AND PUBLIC INVOLVEMENT
DISSEMINATION
The results of the study will be published a peer-reviewed journal and presented at international surgical and diabetes research meetings. Furthermore, to ensure that our findings reach all stakeholders including patients our results will also be presented at relevant patient group meetings as well as local and regional diabetic foot network meetings.
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